Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I Populations
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
SAGA Metals Highlights Radar Titanium Opportunity as North America Confronts Defense Driven Titanium Supply Chain Risks
RETRANSMISSION: Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
